Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Alterations in Langerhans Cell Histiocytosis.

Hematology/oncology clinics of North America - 1 Jun 2025

Gulati Nitya, Peckham-Gregory Erin, Parsons D Williams, Allen Carl E

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by inflammatory lesions with clonal histiocytes. LCH is driven by activating mitogen-activated protein kinase (MAPK) pathway mutations. BRAFV600E is the most common mutation and is associated with more extensive disease at presentation and risks of front-line treatment failure, liver disease, and LCH-associated neurodegeneration....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genomics
Share to Histiocytosis, Langerhans-Cell
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 40133143
DOI: 10.1016/j.hoc.2025.02.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Alterations in Langerhans Cell Histiocytosis.PMID 40133143Read ↗

Genomic Alterations in Langerhans Cell Histiocytosis.Semantic proximity Read ↗

BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.Semantic proximity Read ↗

Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.Semantic proximity Read ↗

BRAF deletion in adult patients with Langerhans cell histiocytosis correlates with multisystem disease and poor outcomeSemantic proximity Read ↗

Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell HistiocytosisSemantic proximity Read ↗

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.Semantic proximity Read ↗

Recent advances in the understanding of Langerhans cell histiocytosisSemantic proximity Read ↗

Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.Semantic proximity Read ↗

Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.Semantic proximity Read ↗

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.Semantic proximity Read ↗

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Semantic proximity Read ↗

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.